CareDx, Inc
NASDAQ:CDNAMedical - Diagnostics & Research
+$1.19 today
- Market cap
- $3.91B
- Beta
- 2.48
- P/E (TTM)
- -154.0
- EPS (TTM)
- -$0.16
Volume 0.54M
Average 0.74M
CDNA Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
CareDx, IncNASDAQ: CDNA
Net Receivables · Q2 FY2026 · quarter ended Jun 2026
Net receivables falls 49.0% from a year ago
Net receivables stood at $34.38M at the end of Q2 FY2026, down 49.0% from a year earlier and down 22.9% from the prior quarter. Over 3 fiscal years it compounded at -13.7% a year.
Context
- Net receivables amounted to 6.4% of total assets at the end of Q2 FY2026, down 8.7 pp from a year earlier.
- Net receivables increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether net receivables keeps falling in the next quarterly balance sheet after a -49.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 42.63M USD
- Year-over-year change
- -34.0%
- 4-year CAGR
- -8.1%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 42.63M | -34.0% |
| FY2024 | 2024-12-31 | 64.61M | +26.5% |
| FY2023 | 2023-12-31 | 51.06M | -23.0% |
| FY2022 | 2022-12-31 | 66.31M | +11.0% |
| FY2021 | 2021-12-31 | 59.76M | — |
Net Receivables vs competitors
How CDNA compares with its peers on the latest reported figures
- CDNA's Jun 2026 net receivables of $34.38M is the lowest of the 8 companies compared; the peer median is $83.61M.
- Its year-over-year change of -49.0% is the lowest of 8, against a peer median of +6.6%.
- Net receivables amounts to 6.4% of total assets for CDNA, versus a peer median of 10.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $421.97M | +36.5% | +6.7% | 15.9% | |
| Jun 2026 | $399.05M | +3.4% | -2.5% | 6.8% | |
| Mar 2026 | $123.8M | +2.8% | +4.3% | 18.4% | |
WGSGeneDx Holdings Corp. | Jun 2026 | $83.61M | +74.1% | +19.7% | 17.4% |
| Mar 2026 | $75.74M | -5.8% | +6.8% | 6.5% | |
BLLNBillionToOne, Inc. | Jun 2026 | $74.89M | +146.1% | — | 10.3% |
| Jun 2026 | $54.18M | +6.6% | +0.5% | 3.6% | |
| Jun 2026 | $34.38M | -49.0% | -13.7% | 6.4% | |
| Peer median (excluding CDNA) | $83.61M | +6.6% | +5.5% | 10.3% | |
Competitors are the stored peer set for CDNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 348.49M | 89.92M | 82.2M | 114.69M | 65.43M |
| Short-term Investments | 0 | 203.17M | 153.22M | 145.96M | 111.78M |
| Net Receivables | 59.76M | 66.31M | 51.06M | 64.61M | 42.63M |
| Inventory | 17.19M | 19.23M | 19.47M | 19.5M | 26.71M |
| Other Current Assets | 0 | 9.22M | 7.76M | 7.07M | 10.59M |
| Total Current Assets | 433.36M | 387.85M | 313.71M | 351.83M | 257.13M |
| Property, Plant & Equipment (Net) | 40.04M | 70.22M | 65.14M | 57.89M | 55.73M |
| Goodwill | 36.98M | 37.52M | 40.34M | 40.34M | 40.34M |
| Intangible Assets | 50.2M | 43.05M | 45.7M | 38.18M | 31.96M |
| Long-term Investments | 0 | 0 | 0 | 0 | 24.17M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 6.05M | 4.35M | 1.94M | 2.81M | 3.9M |
| Total Non-current Assets | 133.26M | 155.14M | 153.11M | 139.22M | 156.1M |
| Total Assets | 566.62M | 542.99M | 466.83M | 491.05M | 413.23M |
| Account Payables | 13.34M | 9.94M | 12.87M | 7.69M | 9.99M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 4.21M | 5.34M | 4.75M | 4.85M | 4.65M |
| Other Current Liabilities | 32.77M | 21.31M | 26.24M | 41.12M | 41.61M |
| Total Current Liabilities | 77.3M | 75.98M | 78.07M | 89.37M | 89.85M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 415K | 0 | 136K | 164K | 181K |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 5.64M | 2.7M | 99.01M | 819K | 418K |
| Total Non-current Liabilities | 23.44M | 36.11M | 127.43M | 23.25M | 20.28M |
| Total Liabilities | 100.75M | 112.08M | 205.5M | 112.62M | 110.13M |
| Common Stock | 52K | 52K | 49K | 51K | 50K |
| Retained Earnings | (383.19M) | (460.44M) | (678.27M) | (626.24M) | (735.36M) |
| Accumulated OCI | (4.67M) | (7.5M) | (6.96M) | (8.57M) | (5.52M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 465.88M | 430.91M | 261.33M | 378.43M | 303.1M |
| Total Debt | 21.35M | 39M | 34.22M | 28.37M | 26.19M |
| Net Debt | (327.13M) | (50.92M) | (47.98M) | (86.32M) | (39.24M) |
CareDx, Inc
NASDAQ:CDNA
Intrinsic Alpha fair value
Locked
Current Price
$74.44
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.